Literature DB >> 14678773

Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23).

Margarita Diez1, Simone Danner, Peter Frey, Bernd Sommer, Matthias Staufenbiel, Karl-Heinz Wiederhold, Tomas Hökfelt.   

Abstract

The role of neuropeptides and the significance of peptidergic mechanisms in neurodegenerative diseases are still unclear. In the periphery, nerve injury results in dramatic changes in the expression of neuropeptides. An important question regards to what extent similar changes occur, and similar mechanisms operate, after lesions and/or degeneration in the brain. The purpose of this work is, therefore, to study neuropeptides with regard to their presence and distribution in the APP23 mouse (HuAPP(751) K670M/N671L under the murine Thy-1 promoter), a model for Alzheimer's disease, or cerebral amyloidosis, using the immunohistochemical technique. In addition, tyrosine hydroxylase and acetylcholinesterase were analyzed. This study shows marked neuropeptide changes in the hippocampal formation and the ventral cortex, whereas the dorsolateral neocortex was less affected. There was a considerable variation with regard to peptide expression among animals of the same age which was related to the variation in Abeta deposition. Dystrophic and varicose fibers containing galanin, neuropeptide Y, enkephalin, and especially cholecystokinin were commonly seen in close proximity to amyloid plaques. In addition, generalized changes were observed, such as increases of enkephalin and neuropeptide Y in stratum lacunosum moleculare and of neuropeptide Y, enkephalin, and dynorphin in mossy fibers. In contrast, cholecystokinin was decreased in mossy fibers. Comparatively small differences were observed between wild-type and transgenic mice with regard to tyrosine hydroxylase (noradrenergic but also dopaminergic fibers) and acetylcholine esterase (mainly cholinergic fibers). The increase of neuropeptides in dystrophic fibers in this model may represent a response to nerve injury caused by the amyloid accumulation and may reflect attempts to counteract degeneration by initiating protective and/or regenerative processes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678773     DOI: 10.1016/j.nbd.2003.08.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  22 in total

1.  Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease.

Authors:  H Kölsch; D Lütjohann; F Jessen; H Urbach; K von Bergmann; W Maier; R Heun
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

2.  Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease.

Authors:  Brian Spencer; Rewati Potkar; Jeff Metcalf; Ivy Thrin; Anthony Adame; Edward Rockenstein; Eliezer Masliah
Journal:  J Biol Chem       Date:  2015-11-30       Impact factor: 5.157

Review 3.  Galanin and its receptors in neurological disorders.

Authors:  Linda Lundström; Anna Elmquist; Tamas Bartfai; Ulo Langel
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 4.  Neuroprotective role for galanin in Alzheimer's disease.

Authors:  Scott E Counts; Sylvia E Perez; Stephen D Ginsberg; Elliott J Mufson
Journal:  Exp Suppl       Date:  2010

5.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

6.  Cholinergic profiles in the Goettingen miniature pig (Sus scrofa domesticus) brain.

Authors:  Laura J Mahady; Sylvia E Perez; Dwaine F Emerich; Lars U Wahlberg; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2016-08-30       Impact factor: 3.215

Review 7.  The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.

Authors:  Carol A Colton; Donna M Wilcock; David A Wink; Judianne Davis; William E Van Nostrand; Michael P Vitek
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

8.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

Review 9.  Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease.

Authors:  J N Crawley
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

Review 10.  Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?

Authors:  S E Counts; S E Perez; E J Mufson
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.